Open Orphan PLC Investor Event Attendance and Presentation (6721D)
21 February 2020 - 6:00PM
UK Regulatory
TIDMORPH
RNS Number : 6721D
Open Orphan PLC
21 February 2020
21 February 2020
RNS REACH
Open Orphan Plc
("Open Orphan" or the "Company")
Investor Event Attendance and Presentation
Open Orphan presents at ShareSoc Growth Company Seminar,
Manchester
Open Orphan , the rapidly growing specialist CRO pharmaceutical
services company which has a focus on orphan drugs and is a world
leader in the provision of virology and vaccine challenge study
services, and has Europe's only 24 bedroom quarantine clinic with
onsite virology lab in Queen Mary's Hospital London, is pleased to
announce that the Company will be attending and presenting at the
ShareSoc Growth Company Seminar on February 25, 2020 at DoubleTree
by Hilton Hotel, One Piccadilly Place, 1 Auburn Street, Manchester
M1 3DG .
Cathal Friel, Open Orphan's Executive Chairman will be
presenting from 18:40 onwards to update existing and potential
investors on the Company's business plans for 2020.
The event will provide an opportunity for investors to hear
about the progress being made by the Company following the
acquisition of hVIVO and the potential for Open Orphan as it moves
rapidly forward rapidly. hVIVO, is a world leader in the provision
of viral challenge studies, vaccine and viral laboratory services
,and supports product development for customers developing
antivirals, vaccines and respiratory therapeutics, all of which are
particularly relevant and topical in the environment of heightened
awareness in light of the current outbreak of coronavirus disease
(COVID-19).It also has Europe's only commercial 24 bed quarantine
clinic and on site virology laboratory at Queen Mary's Hospital in
London.
A link to our investor presentation is already available on our
website at
https://www.openorphan.com/sites/openorphan/files/Open_Orphan_Investor_Deck_0120_1.pdf
Additionally, a link to the video of Open Orphan's presentation
will be made available on the Company website following the
event.
For further information on the Shares Investor Evening and
registration, please visit the event website
https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-25-february-2020/
No new material information will be disclosed at this event.
Enquiries:
Open Orphan Plc Tel: +353 1 5499 341
Cathal Friel, Executive Chairman +353 (0)1 644 0007
Trevor Phillips, Chief Executive Officer +44 (0)20 7347 5350
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor
communication service aimed at assisting listed and unlisted
(including AIM quoted) companies to distribute non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.
Notes to Editors:
Open Orphan is a rapidly growing specialist CRO pharmaceutical
services company which has a focus on orphan drugs and is a world
leader in the provision of virology and vaccine challenge study
services and viral laboratory services. It has Europe's only
24-bedroom quarantine clinic with onsite virology lab in Queen
Mary's Hospital London. hVIVO supports product development for
customers developing antivirals, vaccines and respiratory
therapeutics, all particularly relevant and topical in the
environment of heightened awareness of the Coronavirus in 2020. The
company also has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. No other company in the world has such a
portfolio, with only two competitors globally having 1 challenge
study model each.
Open Orphan comprises of two commercial specialist CRO services
businesses (Venn and hVIVO) and is developing an early stage orphan
drug genomics data platform business. This platform captures
valuable genetic data from patient populations with specific
diseases with designated orphan drug status and incorporating AI
tools. In June 2019, Open Orphan acquired AIM-listed Venn Life
Sciences Holdings plc in a reverse take-over and in January 2020 it
completed the merger with hVIVO plc. Venn, as an integrated drug
development consultancy, offers CMC (c hemistry, manufacturing and
controls) , preclinical, phase I & II clinical trials design
and execution. The merger with hVIVO created a European full pharma
services company broadening the Company's customer base and with
complementary specialist CRO services, widened the range of the
Company's service offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKZGZZNGKGGZM
(END) Dow Jones Newswires
February 21, 2020 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024